Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 6:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 76 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Omeprazole 20mg BID Clear all
Terminated Early Phase 1 Interventional

High Dose Omeprazole in Patients With Pancreatic Cancer

NCT04930991
View directory record Official record
Conditions
Exocrine Pancreatic Cancer
Interventions
Omeprazole
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics

NCT01841489
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Treatment A, Treatment B, Treatment C, Treatment D, Treatment E, Treatment F, Treatment G, Treatment H, Treatment I, Treatment J
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Sep 23, 2026, 6:57 PM EDT
Terminated Phase 4 Interventional Results available

Opioid Free vs. Standard Perioperative Pain Regimen for Anterior Cervical Discectomy and Fusion (ACDF) Surgery

NCT04990804
View directory record Official record
Conditions
Opioid Use, Spinal Diseases, Surgery--Complications, Surgery, Postoperative Pain
Interventions
Opioid Analgesic, Opioid-Free Postoperative Pain Regimen
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Clemizole (EPX-100) in Healthy Participants

NCT07824193
View directory record Official record
Conditions
Drug Drug Interaction
Interventions
EPX-100, Itraconazole, Phenytoin, Omeprazole, Midazolam, Bupropion
Drug
Lead sponsor
Epygenix
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 4 Interventional Results available

Placebo In Chronic Back Pain - Double-Blind Randomized Control Trial

NCT02013427
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Naproxen, Placebo, Omeprazole
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Sep 23, 2026, 6:57 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

GERD and Anti-Reflux Therapy Between Able-bodied and SCI Individuals

NCT02584751
View directory record Official record
Conditions
Gastro Esophageal Reflux Disorder
Interventions
Omeprazole, 24 Hour pH Monitor, Pulmonary Function Examination, Exhaled Nitric Oxide, Exhaled Breath Concentrate (EBC), Bernstein's Acid Clearance Test, Esophageal Motility
Drug · Device · Procedure
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2016 · Synced Sep 23, 2026, 6:57 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Standard Triple Therapy vs Sequential Therapy in Treatment of H Pylori Infection

NCT01723059
View directory record Official record
Conditions
Helicobacter Infection
Interventions
Standard Triple Therapy, Sequential Therapy
Drug
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years to 85 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Results available

Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients

NCT03028103
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma, Mantle Cell Lymphoma, Advanced Solid Tumor, Marginal Zone Lymphoma
Interventions
Tazemetostat, Fluconazole, Omeprazole, Repaglinide
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Tucson, Arizona • Tampa, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2023 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole

NCT00640809
View directory record Official record
Conditions
Bowel Diseases, Inflammatory
Interventions
Celecoxib, Placebo, Ibuprofen plus Omeprazole
Drug · Other
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
408 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
12
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 23, 2026, 6:57 PM EDT
Not listed Phase 4 Interventional

Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE)

NCT04149470
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Omeprazole 20mg BID
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 22 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 23, 2026, 6:57 PM EDT
Withdrawn Phase 2 Interventional

Efficacy Study of Botulinum Toxin (BOTOX) Injections to Treat Vocal Fold Granulomas

NCT01678053
View directory record Official record
Conditions
Contact Ulcer of Vocal Folds, Granuloma of Vocal Cords, Granuloma, Laryngeal, Granuloma
Interventions
onabotulinumtoxinA, omeprazole (proton pump inhibitor)
Drug
Lead sponsor
Phillip Song, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Assessment and Management of Chronic Dyspepsia in Eastern Uganda

NCT04525664
View directory record Official record
Conditions
Helicobacter Pylori Infection, Dyspepsia
Interventions
Clarithromycin 500mg, Amoxicillin 1000 MG, Omeprazole 40 MG, Omeprazole 20 MG Oral Tablet
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects

NCT05657613
View directory record Official record
Conditions
Drug Interactions
Interventions
CYP450 Cocktail and Transporter Substrates with Pacritinib, Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib, Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 3 Interventional Results available

Study of Acid Reflux in Asthma

NCT00069823
View directory record Official record
Conditions
Asthma, Lung Diseases, Lung Diseases, Obstructive
Interventions
Esomeprazole, Placebo proton pump inhibitor
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
20
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Which Supraesophageal Reflux Symptoms Reliably Respond to Proton-Pump-Inhibitor (PPI) Therapy

NCT00170001
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Nexium, Sugar Pill
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 14, 2011 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 2 Interventional

Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis

NCT00123656
View directory record Official record
Conditions
Esophagitis
Interventions
esomeprazole, fluticasone
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Utility of Nexium in Chronic Cough and Reflux Disease

NCT00287339
View directory record Official record
Conditions
Cough, GERD
Interventions
Esomeprazole, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 9, 2012 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Results available

A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma

NCT01001299
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Drug cocktail, RO5185426
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-drug Interaction Study of Aggrenox and Omeprazole in Normal Volunteers

NCT01303445
View directory record Official record
Conditions
Healthy
Interventions
Aggrenox alone, Aggrenox and omeprazole, Omeprazole alone
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 23, 2013 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects

NCT01489943
View directory record Official record
Conditions
Crohn's Disease
Interventions
GSK1605786 500 mg, Midazolam 3 mg, Pioglitazone 15 mg, Omeprazole 40 mg, Rosuvastatin 10 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Sep 23, 2026, 6:57 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

NCT03947385
View directory record Official record
Conditions
Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
Interventions
IDE196, Binimetinib, Crizotinib
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib

NCT01844583
View directory record Official record
Conditions
Solid Tumors, Lymphoma
Interventions
Alisertib, Esomeprazole, Rifampin
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Sarasota, Florida • St Louis, Missouri • Oklahoma City, Oklahoma + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2019 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects

NCT02226783
View directory record Official record
Conditions
Healthy Volunteers Food Interaction Study
Interventions
AZD1722 salt tablet, AZD1722 free base tablet, AZD1722 free base tablet + Omeprazole
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2015 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 2 Interventional Results available

Dermaprazole Cream for Radiation Dermatitis in Head and Neck Cancer

NCT04865731
View directory record Official record
Conditions
Cancer of the Head and Neck
Interventions
Dermaprazole, Aquaphor
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 23, 2026, 6:57 PM EDT